Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor · Non-Small Cell Lung Cancer · Head and Neck Cancer · Melanoma · Gastric Cancer · Renal Cell Carcinoma · Urothelial Carcinoma · Resectable Non-Small-Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 340 (planned)
- Started
- Dec 10, 2019
- Main results expected
- Jul 2033
- Fully finished
- Jul 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Measured over: ~2 years
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Measured over: ~2 years
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Measured over: ~2 years
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Measured over: ~2 years
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Measured over: ~2 years
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Measured over: ~2 years
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["armsInterventionsModule","contactsLocationsModule","statusModule"]}
Trial ID NCT04198766 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC